Convalescent plasma (CP) treatment of coronavirus disease 2019 (COVID-19) has shown significant therapeutic effect when administered early (eg, Argentinian trial showing reduced hospitalization) but has in general been ineffective (eg, REMAP-CAP trial without improvement during hospitalization). To investigate whether the differences in CP used could explain the different outcomes, we compared neutralizing antibodies, anti-spike IgG, and avidity of CP used in the REMAP-CAP and Argentinian trials and in convalescent vaccinees. We found no difference between the trial plasmas, emphasizing initial patient serostatus as treatment efficacy predictor. By contrast, vaccinee CP showed significantly higher titers and avidity, being preferable for future CP treatment. Clinical Trials Registration. NCT02735707 and NCT04479163.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420400 | PMC |
| http://dx.doi.org/10.1093/infdis/jiad070 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Memory responses to ovalbumin-immunization in Mojave desert tortoises.
Dev Comp Immunol
January 2025
Biology Department, University of Colorado - Pueblo, 2200 Bonforte Ave., Pueblo, CO, 81001, USA.
We immunized three groups of Mojave desert tortoises (Gopherus agassizii): a group immunized twice, a group immunized once, and a group sham-immunized. We used the antigen, ovalbumin (OVA), with Freund's adjuvant to elicit antibody responses similar to those induced by extracellular bacteria. All tortoises have relatively high levels of B1 lymphocytes and natural antibodies (NAbs), and the goal of this study was to quantify B2 lymphocyte activity (antibody production and potential proliferation) that occurs in primary and secondary immunizations against this constitutive, first line of humoral defense.
View Article and Find Full Text PDFSafety and immunogenicity of a bivalent norovirus vaccine candidate in infants from 6 weeks to 5 months of age: A phase 2, randomized, double-blind trial.
Hum Vaccin Immunother
December 2025
Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland.
As infants suffer significant morbidity and mortality due to norovirus-related acute gastroenteritis (AGE), we assessed four formulations of the bivalent virus-like particle (VLP) vaccine candidate (HIL-214) in Panamanian and Colombian infants. 360 infants aged 6 weeks to 5 months were randomly allocated to 8 groups to receive three doses of HIL-214 or two doses of HIL-214 and one dose of placebo (Days 1, 56 and 112), where HIL-214 doses contained 15/15, 15/50, 50/50 or 50/150 μg of GI.1/GII.
View Article and Find Full Text PDFDoes Tobacco Smoking Affect Vaccine-Induced Immune Response? A Systematic Review and Meta-Analysis.
Vaccines (Basel)
November 2024
Department of Medical, Movement and Wellbeing Sciences, University of Naples "Parthenope", 80133 Naples, Italy.
. Causing approximately 8 million deaths each year, tobacco smoking represents a significant public health concern. Evidence shows that smoking significantly impairs antibody production and immune cell activity following vaccination.
View Article and Find Full Text PDFMTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates.
NPJ Vaccines
November 2024
Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
The only currently licensed vaccine against tuberculosis (TB), Bacille Calmette Guérin (BCG), is insufficient to control the epidemic. MTBVAC is a live attenuated strain of Mycobacterium tuberculosis (M.tb) and is one the most advanced TB vaccine candidates in the pipeline.
View Article and Find Full Text PDFProC6C, a novel multi-stage malaria vaccine, elicits functional antibodies against the minor and central repeats of the Circumsporozoite Protein in human adults.
Front Immunol
November 2024
Department for Congenital Disorders, Statens Serum Institut (SSI), Copenhagen, Denmark.
Introduction: ProC6C is a multi-stage malaria vaccine which includes Circumsporozoite Protein (PfCSP), Pfs48/45 and Pfs230 sequences, designed to elicit functional antibodies that prevent sporozoite invasion of human hepatocytes (PfCSP) and parasite development in mosquitoes (Pfs48/45 and Pfs230). ProC6C formulated on Alhydrogel was evaluated in combination with Matrix-M in a Phase 1 trial in Burkina Faso. The PfCSP antibody responses were assessed for magnitude, specificity, avidity and functionality.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!